Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
11 avr. 2019 10h00 HE
|
Immuron Limited
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé
31 janv. 2019 02h00 HE
|
Deinove
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
31 janv. 2019 02h00 HE
|
Deinove
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...
Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
31 janv. 2018 09h30 HE
|
Immuron Limited
Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of...
SteraMist™ Contributes to Substantial Reduction in Clostridium Difficile Burden in Hospital
03 avr. 2017 16h05 HE
|
TOMI Environmental Solutions, Inc.
BEVERLY HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination and infection prevention company that specializes in...
Paratek Presents Data from Omadacycline Clinical Development Program at ECCMID
11 avr. 2016 07h30 HE
|
Paratek Pharmaceuticals
Pooled analysis from Phase 2 and truncated Phase 3 studies demonstrates comparable safety and efficacy profiles for omadacycline compared with linezolid Single dose randomized trial...
Paratek Presents Pre-Clinical Data on the Effects of Omadacycline on Clostridium Difficile
11 avr. 2016 07h30 HE
|
Paratek Pharmaceuticals
AMSTERDAM, Netherlands, April 11, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today presented data from two pre-clinical studies evaluating the impact of omadacycline on...
C. difficile Infection Increases Hospital Costs by 40 Percent Per Case, Study Finds
10 déc. 2015 09h27 HE
|
Premier, Inc.
Patients with C. diff stay in hospital 55 percent longer and are 77 percent more likely to be readmitted CHARLOTTE, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Clostridium difficile (C. diff),...
Fecal transplant pills: Large-scale production begins
28 oct. 2015 08h39 HE
|
OpenBiome
BOSTON, Oct. 28, 2015 (GLOBE NEWSWIRE) -- A new pill created by a team of MIT-trained researchers provides fecal transplant therapy without requiring the traditional, more invasive stool delivery...
Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
27 févr. 2014 09h05 HE
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwired - Feb 27, 2014) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with...